Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine whether VI-1121 is safe, well tolerated, and effective as a daily treatment for Alzheimer's disease that is worsening despite current treatment.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
VIVUS LLC
Collaborators
NCT07666113 · Alzheimer's Disease (AD)
NCT07214727 · Alzheimer's Disease
NCT06745583 · Mild, Moderate, or Severe Alzheimer's Disease
NCT07040904 · Mindfulness, Alzheimer's Disease Related Dementia
NCT05592678 · Alzheimer's Disease (AD), Dementia, and more
San Francisco, California
Santa Monica, California
Sunrise, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions